Charles River Laboratories International, Inc. reported a disappointing net loss of $276.56 million for the fourth quarter of 2025, alongside a revenue drop to $994.23 million, reflecting a tough year in the financial markets. While the company managed to beat analyst expectations with an adjusted EPS of $2.39, marking a 10.2% year-over-year decline, it has issued a cautious revenue outlook for 2026, projecting minimal growth. With shares down approximately 22% year-to-date and concerns about industry shifts and pricing pressures mounting, Charles River faces a challenging path to regain investor confidence.
“Charles River Laboratories International · is down · percentage · more than -4%”
“Charles River Laboratories International, Inc. · reported · fourth-quarter 2025 adjusted earnings per share (EPS) · $2.39”
“Charles River Laboratories International, Inc. · reported · full-year 2025 EPS · $10.28”
“Charles River Laboratories International, Inc. · issued · full-year 2026 outlook · expected total revenues to be at least flat to 1.5% growth”
“Charles River Laboratories International · has a one-month return of · 28% decline · 28.08%”
“Charles River Laboratories International · has a year-to-date return of · 22% decline · 21.94%”
“Charles River Laboratories International · has a one-year total shareholder return of · 4.24% decline · 4.24%”
“Charles River Laboratories International · is considered · 26.8% undervalued · 26.8%”
“Charles River Laboratories International · has a fair value of · $215.73 · $215.73”
“Charles River Laboratories International · has a consensus price target of · $177.067 · $177.067”
“Charles River Laboratories International · may encounter risks such as · a faster shift toward non-animal testing · faster shift toward non-animal testing”
“Charles River Laboratories International · may encounter risks such as · tougher CRO pricing · tougher CRO pricing”